FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155264814> ?p ?o ?g. }

• W2155264814 endingPage "35852" @default.
• W2155264814 startingPage "35845" @default.
• W2155264814 abstract "Myocardin (MYOCD) is a transcriptional co-activator that promotes cardiac or smooth muscle gene programs through its interaction with myocyte-enhancing factor (MEF2) or serum-response factor (SRF). Isoforms of MYOCD with a truncated amino terminus show increased activity when compared with those with the full-length amino terminus, but how this is achieved remains unknown. We identified a rare human sequence variation in MYOCD in a patient with congenital heart disease that resulted in a missense mutation at codon 259 (K259R). This variation created a hypomorphic cardiac isoform with impaired SRF binding and transactivation capacity but did not impair the smooth muscle isoform of MYOCD, which lacks the amino terminus. Consistent with differential effects of the amino terminus on the K259R mutation, we found that the cardiac-specific amino terminus acted in an autoinhibitory fashion to bind MYOCD via specific negatively charged residues and thereby repressed SRF-dependent MYOCD activity. This effect was exaggerated in the MYOCD-K259R mutant. The amino terminus was sufficient to impair MYOCD-dependent fibroblast conversion into smooth muscle cells as well as cardiomyocyte hypertrophy. These findings identify a novel mechanism that regulates levels of MYOCD-dependent activation of the SRF genetic program differentially in cardiac and smooth muscle. Myocardin (MYOCD) is a transcriptional co-activator that promotes cardiac or smooth muscle gene programs through its interaction with myocyte-enhancing factor (MEF2) or serum-response factor (SRF). Isoforms of MYOCD with a truncated amino terminus show increased activity when compared with those with the full-length amino terminus, but how this is achieved remains unknown. We identified a rare human sequence variation in MYOCD in a patient with congenital heart disease that resulted in a missense mutation at codon 259 (K259R). This variation created a hypomorphic cardiac isoform with impaired SRF binding and transactivation capacity but did not impair the smooth muscle isoform of MYOCD, which lacks the amino terminus. Consistent with differential effects of the amino terminus on the K259R mutation, we found that the cardiac-specific amino terminus acted in an autoinhibitory fashion to bind MYOCD via specific negatively charged residues and thereby repressed SRF-dependent MYOCD activity. This effect was exaggerated in the MYOCD-K259R mutant. The amino terminus was sufficient to impair MYOCD-dependent fibroblast conversion into smooth muscle cells as well as cardiomyocyte hypertrophy. These findings identify a novel mechanism that regulates levels of MYOCD-dependent activation of the SRF genetic program differentially in cardiac and smooth muscle. Myocardin (MYOCD) 2The abbreviations used are:MYOCDmyocardinMYOCD935cardiac isoform of MYOCDMYOCDΔMHDsmooth muscle isoform of MYOCDMHDmyocardin homology domainSRFserum-response factorMEF2myocyte-enhancing factorSM22α22-kilodalton smooth muscle protein α (transgel-lin)ANFatrial natriuretic factor (Nppa)SM-α-actinsmooth muscle α-actin (ACTA2)Co-IPco-immunoprecipitationEMSAelectromobility shift assayMRTFmyocardin-related transcription factorPEphenyleph-rineTRITCtetramethylrhodamine isothiocyanateDAPI4′,6-diamidino-2-phenylindoleRT-PCRreal-time PCRWTwild typeDNdominant-negativeLucluciferaseHAhemagglutinin was the first recognized member of a family of transcriptional co-activators that binds to serum-response factor (SRF) to activate cardiac or smooth muscle gene programs (1Wang D. Chang P.S. Wang Z. Sutherland L. Richardson J.A. Small E. Krieg P.A. Olson E.N. Cell. 2001; 105: 851-862Abstract Full Text Full Text PDF PubMed Scopus (756) Google Scholar). The two other MYOCD-related transcription factors (MRTF), MRTF-A (also known as MAL, MKL1, or BSAC) and MRTF-B (MKL2), also co-activate SRF, but for unknown reasons, MRTF-B is a weaker activator than either MYOCD or MRTF-A (reviewed in Refs. (2Wang D.Z. Li S. Hockemeyer D. Sutherland L. Wang Z. Schratt G. Richardson J.A. Nordheim A. Olson E.N. Proc. Natl. Acad. Sci. U. S. A. 2002; 99: 14855-14860Crossref PubMed Scopus (408) Google Scholar, 3Wang D.Z. Olson E.N. Curr. Opin. Genet. Dev. 2004; 14: 558-566Crossref PubMed Scopus (183) Google Scholar, 4Cen B. Selvaraj A. Prywes R. J. Cell. Biochem. 2004; 93: 74-82Crossref PubMed Scopus (137) Google Scholar, 5Parmacek M.S. Circ. Res. 2007; 100: 633-644Crossref PubMed Scopus (211) Google Scholar). MYOCD, MRTF-A, and MRTF-B are all co-expressed in the developing myocardium early in gestation and are expressed in distinct populations of smooth muscle cells later during development (6Li S. Wang D.Z. Wang Z. Richardson J.A. Olson E.N. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 9366-9370Crossref PubMed Scopus (302) Google Scholar, 7Oh J. Richardson J.A. Olson E.N. Proc. Natl. Acad. Sci. U. S. A. 2005; 102: 15122-15127Crossref PubMed Scopus (127) Google Scholar, 8Li S. Chang S. Qi X. Richardson J.A. Olson E.N. Mol. Cell. Biol. 2006; 26: 5797-5808Crossref PubMed Scopus (153) Google Scholar, 9Li J. Zhu X. Chen M. Cheng L. Zhou D. Lu M.M. Du K. Epstein J.A. Parmacek M.S. Proc. Natl. Acad. Sci. U. S. A. 2005; 102: 8916-8921Crossref PubMed Scopus (123) Google Scholar). In mice, targeted deletion of the SRF interaction domain in MYOCD led to embryonic lethality from cardiovascular defects (6Li S. Wang D.Z. Wang Z. Richardson J.A. Olson E.N. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 9366-9370Crossref PubMed Scopus (302) Google Scholar). MYOCD-null mice died midgestation, by embryonic day 10.5, apparently from insufficient smooth muscle specification in the distal aorta and placenta (6Li S. Wang D.Z. Wang Z. Richardson J.A. Olson E.N. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 9366-9370Crossref PubMed Scopus (302) Google Scholar). Furthermore, conditional deletion of MYOCD from neural crest resulted in defects in neural crest-derived smooth muscle differentiation (10Huang J. Cheng L. Li J. Chen M. Zhou D. Lu M.M. Proweller A. Epstein J.A. Parmacek M.S. J. Clin. Investig. 2008; 118: 515-525PubMed Google Scholar). myocardin cardiac isoform of MYOCD smooth muscle isoform of MYOCD myocardin homology domain serum-response factor myocyte-enhancing factor 22-kilodalton smooth muscle protein α (transgel-lin) atrial natriuretic factor (Nppa) smooth muscle α-actin (ACTA2) co-immunoprecipitation electromobility shift assay myocardin-related transcription factor phenyleph-rine tetramethylrhodamine isothiocyanate 4′,6-diamidino-2-phenylindole real-time PCR wild type dominant-negative luciferase hemagglutinin Cardiac and smooth muscle both express MYOCD, but the smooth muscle isoform (MYOCDΔMHD) utilizes an alternate start codon that leads to a partial truncation of the MYOCD homology domain (MHD) (11Creemers E.E. Sutherland L.B. Oh J. Barbosa A.C. Olson E.N. Mol. Cell. 2006; 23: 83-96Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar). The MHD, found in the amino terminus of cardiac MYOCD, contains three RPEL motifs that regulate actin-dependent nuclear localization of MRTF-A/B but not of MYOCD (12Miralles F. Posern G. Zaromytidou A.I. Treisman R. Cell. 2003; 113: 329-342Abstract Full Text Full Text PDF PubMed Scopus (1068) Google Scholar). It is thought that actin dynamics do not regulate MYOCD because two of the three RPEL motifs in MYOCD are evolutionarily divergent from the consensus sequence, whereas both MRTFs have three highly conserved RPEL motifs. Although MYOCD is constitutively nuclear, its MHD contains a binding site for myocyte-enhancing factor 2 (MEF2), which activates portions of the cardiac gene program that are distinct from the SRF-dependent program (11Creemers E.E. Sutherland L.B. Oh J. Barbosa A.C. Olson E.N. Mol. Cell. 2006; 23: 83-96Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar). MYOCD truncations that lack the MHD show increased SRF-dependent transactivation both in vitro (1Wang D. Chang P.S. Wang Z. Sutherland L. Richardson J.A. Small E. Krieg P.A. Olson E.N. Cell. 2001; 105: 851-862Abstract Full Text Full Text PDF PubMed Scopus (756) Google Scholar) and in vivo (13Wang Z. Wang D.Z. Hockemeyer D. McAnally J. Nordheim A. Olson E.N. Nature. 2004; 428: 185-189Crossref PubMed Scopus (464) Google Scholar), but how this is achieved is unknown. Multiple transcription factors interact with and synergistically regulate the MYOCD transcriptional complex on DNA. The Jagged/Notch signal transduction pathway is able to inhibit MYOCD-dependent SRF-co-activation via HRT2, a transcriptional repressor, during smooth muscle differentiation (14Proweller A. Pear W.S. Parmacek M.S. J. Biol. Chem. 2005; 280: 8994-9004Abstract Full Text Full Text PDF PubMed Scopus (102) Google Scholar). Depending on the context, the GATA4/5/6 family of transcription factors is able to either activate or inhibit MYOCD-dependent transactivation (15Oh J. Wang Z. Wang D. Lien C. Xing W. Olson E. Mol. Cell. Biol. 2004; 24: 8519-8528Crossref PubMed Scopus (54) Google Scholar). Another MYOCD regulator is ELK1, which is necessary for SRF-dependent induction of MYOCD-independent immediate early genes (13Wang Z. Wang D.Z. Hockemeyer D. McAnally J. Nordheim A. Olson E.N. Nature. 2004; 428: 185-189Crossref PubMed Scopus (464) Google Scholar). The SRF-binding motifs in MYOCD and ELK1 show strong homology to one another, and ELK1 utilizes this motif to compete with MYOCD for SRF (13Wang Z. Wang D.Z. Hockemeyer D. McAnally J. Nordheim A. Olson E.N. Nature. 2004; 428: 185-189Crossref PubMed Scopus (464) Google Scholar). In this way, ELK1 is able to deactivate some MYOCD target genes in favor of growth over differentiation (13Wang Z. Wang D.Z. Hockemeyer D. McAnally J. Nordheim A. Olson E.N. Nature. 2004; 428: 185-189Crossref PubMed Scopus (464) Google Scholar). Although these and other transcription factors are known to synergistically regulate MYOCD-dependent activity, it is unknown whether there are mechanisms that act directly on MYOCD to regulate the SRF interaction or how the MHD-dependent decrease in MYOCD activity occurs. Here, we describe how a rare human MYOCD missense mutation, resulting in a lysine to arginine substitution at codon 259 (K259R), revealed a novel mechanism by which MYOCD activity is regulated. The mutation, which occurred in a subject with thickened pulmonary valves, resulted in a hypomorphic cardiac MYOCD, but did not affect activity of the smooth muscle MYOCD lacking the MHD. In exploring how the MHD influenced the K259R effects, we found that the amino terminus regulated MYOCD activity in an autoinhibitory fashion by binding to MYOCD and disrupting SRF-dependent activation. The MYOCD K259R mutant showed a more pronounced response to the autoinhibitory activity of the MHD. These findings suggest a novel mechanism for regulation of MYOCD activity in cardiac versus smooth muscle. Plasmid Construction—FLAG-MYOCD truncations, atrial natriuretic factor-luciferase (ANF-Luc), and smooth muscle 22α-luciferase (SM22α-Luc) have been described (1Wang D. Chang P.S. Wang Z. Sutherland L. Richardson J.A. Small E. Krieg P.A. Olson E.N. Cell. 2001; 105: 851-862Abstract Full Text Full Text PDF PubMed Scopus (756) Google Scholar). MHD truncations were created by PCR amplification of MYOCD cDNA with added 5′ end NotI and 3′ end XbaI restriction enzyme sites. K259R, R71R115 → AA, and D130E135 → AA were mutated with the QuikChange II kit (Stratagene), according to the manufacturer's instructions. All mutations were confirmed by sequencing. Primer sequences are available upon request. Cell Culture and Transfections—Cos-1 cells (American Type Culture Collection) were maintained and passaged as described (16Zhao Y. Ransom J.F. Li A. Vedantham V. von Drehle M. Muth A.N. Tsuchihashi T. McManus M.T. Schwartz R.J. Srivastava D. Cell. 2007; 129: 303-317Abstract Full Text Full Text PDF PubMed Scopus (1196) Google Scholar). Transfections were carried out in 12-well dishes unless otherwise indicated. Cells were transfected with 50 ng of each reporter plasmid and 100 ng of each cDNA for 40-44 h and harvested in passive lysis buffer (Promega). Total amounts of DNA were kept constant with corresponding expression vector without a cDNA insert. A CMV-LacZ plasmid was co-transfected for internal transfection efficiency control (1Wang D. Chang P.S. Wang Z. Sutherland L. Richardson J.A. Small E. Krieg P.A. Olson E.N. Cell. 2001; 105: 851-862Abstract Full Text Full Text PDF PubMed Scopus (756) Google Scholar). Western analysis was performed for all transfected proteins to ensure equal expression. Luciferase assays were performed with a PerkinElmer Life Sciences Victor3 plate reader as described (16Zhao Y. Ransom J.F. Li A. Vedantham V. von Drehle M. Muth A.N. Tsuchihashi T. McManus M.T. Schwartz R.J. Srivastava D. Cell. 2007; 129: 303-317Abstract Full Text Full Text PDF PubMed Scopus (1196) Google Scholar). CH310T1/2 cells (American Type Culture Collection) were maintained and passaged as described, except that the plates were coated with 1! gelatin for 30 min before passaging (17Wang Z. Wang D.Z. Pipes G.C. Olson E.N. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 7129-7134Crossref PubMed Scopus (433) Google Scholar). Transfections were performed with FuGENE 6 (Roche Applied Science) according to the manufacturer's instructions. Twenty-four hours after transfection, the cells were switched to Dulbecco's modified Eagle's medium containing 2! horse serum. Seven days later, immunocytochemistry and quantitative real-time (RT) PCR (TaqMan, Applied Biosystems) were performed. For each experiment, 500 ng of each cDNA was used for each well of a six-well plate. A CMV-eGFP plasmid (100 ng, Amaxa) was co-transfected as an internal control for transfection efficiency. Cells were transfected and counted double-blind. Conversion efficiency was calculated as the number of SM-α-actin-positive cells divided by the number of green fluorescent protein-positive cells. Primary cardiomyocytes were harvested from 0-2-day-old Sprague-Dawley rats as described (18Xing W. Zhang T.C. Cao D. Wang Z. Antos C.L. Li S. Wang Y. Olson E.N. Wang D.Z. Circ. Res. 2006; 98: 1089-1097Crossref PubMed Scopus (139) Google Scholar) with minor modifications. The cardiomyocytes were enzymatically separated with 1 μg/ml pancreatin, plated on 0.1! gelatin-coated dishes, and infected 1 day later with lentivirus (pLenti6 Gateway System, Invitrogen) overexpressing protein under control of the EF1 promoter. Twenty-four hours later, phenylephrine (PE) was added to the medium (final concentration, 20 μm.) Forty-eight hours after infection, immunofluorescence and quantitative RT-PCR were performed. Area calculations of the α-actinin-positive cells were made using the Image-Pro 5.0 software; control cells without PE were set at an arbitrary value of 100, and then each condition was set proportionate to the control cells. Cardiomyocyte infection and area calculations were performed double-blind. Quantitative RT-PCR—Whole RNA was purified with TRI Reagent (Applied Biosystems), treated with DNA-free DNase (Ambion), and synthesized into cDNA with poly(dT) primers (Superscriptase III kit, Invitrogen) according to the manufacturer's instructions. RT-PCR was performed with Applied Biosystems 2× master mix and TaqMan primers (see supplemental Table S1) as described (16Zhao Y. Ransom J.F. Li A. Vedantham V. von Drehle M. Muth A.N. Tsuchihashi T. McManus M.T. Schwartz R.J. Srivastava D. Cell. 2007; 129: 303-317Abstract Full Text Full Text PDF PubMed Scopus (1196) Google Scholar). Analysis was performed using the 2(-ΔΔCt) method. Protein Interaction Assays—Co-immunoprecipitation (Co-IP) and electromobility shift assays (EMSA) were performed as described (1Wang D. Chang P.S. Wang Z. Sutherland L. Richardson J.A. Small E. Krieg P.A. Olson E.N. Cell. 2001; 105: 851-862Abstract Full Text Full Text PDF PubMed Scopus (756) Google Scholar). For Co-IP, 1 μg of FLAG-MYOCD and 100 ng of hemagglutinin-tagged SRF were transfected and harvested 40 h later. For EMSA, protein was translated from 1 μg of each plasmid with the Promega TnT kit. An oligonucleotide containing the c-fos CArG box (1Wang D. Chang P.S. Wang Z. Sutherland L. Richardson J.A. Small E. Krieg P.A. Olson E.N. Cell. 2001; 105: 851-862Abstract Full Text Full Text PDF PubMed Scopus (756) Google Scholar) was 32P-labeled with the Roche Applied Science high prime labeling kit. Quantification of the binding efficiency was made using the ImageJ v1.4 software. Immunocytochemistry and Western Blot—Immunocytochemistry and Western analysis were performed as described (16Zhao Y. Ransom J.F. Li A. Vedantham V. von Drehle M. Muth A.N. Tsuchihashi T. McManus M.T. Schwartz R.J. Srivastava D. Cell. 2007; 129: 303-317Abstract Full Text Full Text PDF PubMed Scopus (1196) Google Scholar). Antibodies were diluted as follows: mouse anti-SM-α-actin (Sigma), 1:1000; mouse anti-α-actinin (Sigma), 1:200; mouse anti-FLAG (M2, Sigma) 1:5000 (Western) or 1:500 (immunocytochemistry); and mouse anti-Myc (9a7, Santa Cruz Biotechnology), 1:1000. Fluorescein isothiocyanate- or TRITC-conjugated goat anti-mouse secondary antibodies were used for immunocytochemistry, and alkaline phosphatase-conjugated goat anti-mouse or goat anti-rabbit antibodies were used for Western analysis (Jackson Immunologicals). A Unique MYOCD Sequence Variant in a Patient with a Congenital Cardiac Malformation—In a genetic screen of subjects with congenital cardiovascular malformations, 3V. Garg and D. Srivastava, unpublished data. we found an adenosine-to-guanosine sequence variant in the gene encoding MYOCD (GenBank™ accession number AF532596) that resulted in an arginine substitution for a highly conserved lysine at codon 259 (A776G, supplemental Fig. 1 A). This Hispanic patient had a thickened and stenotic pulmonary valve that obstructed flow of blood from the right ventricle to the pulmonary artery. The frequency of the K259R sequence variation was evaluated in the Dallas Heart Study population of control subjects (19Victor R.G. Haley R.W. Willett D.L. Peshock R.M. Vaeth P.C. Leonard D. Basit M. Cooper R.S. Iannacchione V.G. Visscher W.A. Staab J.M. Hobbs H.H. Am. J. Cardiol. 2004; 93: 1473-1480Abstract Full Text Full Text PDF PubMed Scopus (439) Google Scholar). We found the sequence variation in 1 out of 1137 control individuals, indicating that this is an extremely rare genetic variant. This subject was also Hispanic (out of 212 total Hispanic controls). The valve morphology of the control individual is unknown, and subclinical disease could not be excluded. Sequence alignments show that Lys-259 has been evolutionarily conserved from fruit flies to humans (supplemental Fig. 1B), suggesting that Lys-259 is under selective pressure and may be important for MYOCD function. This residue is also conserved in MRTF-A, but MRTF-B contains an arginine at the corresponding codon (Arg-288, supplemental Fig. 1B). Interestingly, MRTF-B is transcriptionally less active than MYOCD or MRTF-A on most promoters (2Wang D.Z. Li S. Hockemeyer D. Sutherland L. Wang Z. Schratt G. Richardson J.A. Nordheim A. Olson E.N. Proc. Natl. Acad. Sci. U. S. A. 2002; 99: 14855-14860Crossref PubMed Scopus (408) Google Scholar). Cardiac but Not Smooth Muscle Myocardin K259R Is Hypomorphic and Has Reduced SRF Affinity—MYOCD Lys-259 is not contained in the SRF-binding B-box, but does lie within the lysine-rich basic domain that is necessary for SRF binding (Fig. 1A) (1Wang D. Chang P.S. Wang Z. Sutherland L. Richardson J.A. Small E. Krieg P.A. Olson E.N. Cell. 2001; 105: 851-862Abstract Full Text Full Text PDF PubMed Scopus (756) Google Scholar). We therefore hypothesized that K259R might affect MYOCD-dependent promoter activation of SRF-dependent targets (1Wang D. Chang P.S. Wang Z. Sutherland L. Richardson J.A. Small E. Krieg P.A. Olson E.N. Cell. 2001; 105: 851-862Abstract Full Text Full Text PDF PubMed Scopus (756) Google Scholar). Transient co-transfection of the 935-amino acid, cardiac-specific isoform of MYOCD (MYOCD935) with luciferase reporters driven by the SM22α-Luc or ANF-Luc promoter showed that K259R MYOCD935 was hypomorphic when compared with wild type (WT) MYOCD935 (Fig. 1, B and C). The reduced activity was not due to changes in cellular localization, as WT and K259R MYOCD935 both localized to the nucleus (Fig. 1D). We tested whether the reduction in MYOCD activity was due to a corresponding reduction in binding between MYOCD and SRF. In Co-IP assays, we were unable to detect an interaction between MYOCD935 K259R and SRF, but WT MYOCD935 showed normal SRF binding (Fig. 1E). In a more sensitive test involving DNA-protein interactions, EMSA revealed that MYOCD935 K259R could interact with SRF, but this interaction was harder to detect than with WT MYOCD935 (Fig. 1F). Since MRTF-B is a weaker activator than MYOCD or MRTF-A, we hypothesized this may be due, in part, to the evolutionarily divergent arginine at codon 288. Mutation of arginine 288 to lysine (R288K), the residue present in MYOCD or MRTF-A, increased MRTF-B-dependent activation of SM22α-Luc nearly 5-fold (Fig. 1G). Although this was still well below the levels achieved with MYOCD or MRTF-A in vitro, it demonstrated that the two basic amino acids are not functionally equivalent in this domain and that an arginine at this residue of the MYOCD family of proteins is sufficient to limit the transactivation potential of MYOCD proteins. Since the cardiac (MYOCD935) and smooth muscle (MYOCDΔMHD) isoforms also have different levels of activity, we tested whether K259R affected MYOCDΔMHD in a similar fashion to the cardiac isoform. In contrast to what was observed with MYOCD935, K259R MYOCDΔMHD was functionally normal in luciferase reporter assays using the SM22α promoter (Fig. 2A). Unlike with K259R MYOCD935, K259R MYOCDΔMHD appeared to interact with SRF similar to WT MYOCD as assessed by Co-IP (Fig. 2B) and EMSA (Fig. 2C). The MYOCD MHD Inhibits MYOCD-dependent Transcription in Vitro by Binding to MYOCD and Blocking Its Interaction with SRF—Because truncating the MHD rescued the K259R hypomorph despite being in a distant domain, we hypothesized that the MHD of MYOCD might normally act as an intramolecular autoinhibitor, consistent with the increased activity of MYOCDΔMHD (20Peterson J.R. Golemis E.A. J. Cell. Biochem. 2004; 93: 68-73Crossref PubMed Scopus (23) Google Scholar, 21Zaromytidou A.I. Miralles F. Treisman R. Mol. Cell. Biol. 2006; 26: 4134-4148Crossref PubMed Scopus (80) Google Scholar). If this were the case, the MHD, even when separated from the rest of MYOCD, might bind to other domains in MYOCD to mask or allosterically compete for SRF binding. Consistent with this, we found that expression of amino acids 1-195 inhibited transactivation by MYOCDΔMHD on the SRF-dependent reporters described earlier. Amino acids 1-149 also inhibited MYOCD activity in a dose-dependent manner; however, amino acids 1-129 did not (Fig. 3A). Truncation of the MHD amino terminus revealed that amino acids 1-30, but not 30-60, were dispensable for inhibition of MYOCD transactivation (Fig. 3A). Thus, the minimal MYOCD inhibitory domain appeared to lie between amino acids 30 and 149. The MHD of MRTF-A has been well characterized as an actin-dependent regulator of nuclear localization (12Miralles F. Posern G. Zaromytidou A.I. Treisman R. Cell. 2003; 113: 329-342Abstract Full Text Full Text PDF PubMed Scopus (1068) Google Scholar, 21Zaromytidou A.I. Miralles F. Treisman R. Mol. Cell. Biol. 2006; 26: 4134-4148Crossref PubMed Scopus (80) Google Scholar); however, MYOCD is thought to be constitutively nuclear (1Wang D. Chang P.S. Wang Z. Sutherland L. Richardson J.A. Small E. Krieg P.A. Olson E.N. Cell. 2001; 105: 851-862Abstract Full Text Full Text PDF PubMed Scopus (756) Google Scholar, 12Miralles F. Posern G. Zaromytidou A.I. Treisman R. Cell. 2003; 113: 329-342Abstract Full Text Full Text PDF PubMed Scopus (1068) Google Scholar). Similar to MRTF-A, MYOCD contains two conserved RPEL motifs in the minimal inhibitory MHD. In previous reports, mutation of the conserved arginines to alanine of the RPEL motif disrupted the MHD-dependent nuclear localization of MRTF-A (12Miralles F. Posern G. Zaromytidou A.I. Treisman R. Cell. 2003; 113: 329-342Abstract Full Text Full Text PDF PubMed Scopus (1068) Google Scholar). We found that mutation of the conserved arginines (R71A, R115A) of the two RPEL motifs had no effect on the ability of the MHD to inhibit MYOCD activity, suggesting that the RPEL motifs are not necessary for autoinhibition (Fig. 3B). Another known motif within the MHD is the MEF2-binding site, located in the first 17 amino acids of MYOCD (22Creemers E.E. Sutherland L.B. McAnally J. Richardson J.A. Olson E.N. Development (Camb.). 2006; 133: 4245-4256Crossref PubMed Scopus (114) Google Scholar). Because amino acids 1-30 were not necessary for inhibition, the MEF2-binding domain may also be dispensable for inhibition of SRF-dependent MYOCD activity (Fig. 3A). Since the RPEL- and MEF2-binding motif were not necessary and MHD1-129 was insufficient to inhibit MYOCD co-activation, we focused on amino acids 129-149. Sequence analysis identified no recognizable motifs, but revealed two acidic residues that are conserved from humans to amphibians: aspartate 130 (Asp-130) and glutamate 135 (Glu-135, supplemental Fig. 1C). Mutation of these two negatively charged residues to uncharged alanines (DE → AA) disrupted the autoinhibition, effectively mapping some of the essential residues required for inhibition (Fig. 3B). Next, we investigated whether the MHD was a true autoinhibitory domain that directly binds to MYOCD via intramolecular interactions. In Co-IP experiments, truncated MHD that contained the minimal autoinhibitory domain (30-149) was able to bind to MYOCD, although the 30-149 construct had less affinity than the 1-149 construct (Fig. 3C). Furthermore, mutation of both Asp-130 and Glu-135 disrupted MYOCD-MHD interactions, whereas mutation of the conserved RPEL motifs did not. Autoinhibitory domains generally have to retain intramolecular binding to inhibit protein activity, which may explain why the DE → AA mutations were not inhibitory in the luciferase reporter assays. To seek further evidence of a physical interaction between MYOCD and the MHD, we developed a mammalian two-hybrid assay, with the MHD-1-149 conjugated to the DNA-binding domain of GAL4 (GAL4-MHD). We observed that MYOCD was able to co-activate the UAS-luciferase reporter in the presence of GAL4-MHD (Fig. 3E). Furthermore, SRF was able to inhibit the MYOCD-dependent activation of GAL4-MHD, which suggested that the MHD and SRF could compete for interaction with MYOCD (Fig. 3E). Since the MHD could compete with SRF for binding to MYOCD and the MHD was necessary for K259R to behave as a hypomorph, we hypothesized that K259R would confer greater autoinhibition when compared with WT MYOCD. Consistent with this hypothesis, K259R MYOCDΔMHD displayed more MHD-dependent inhibition than WT MYOCDΔMHD on the SM22α promoter (Fig. 3F). The MYOCD MHD Inhibits MYOCD-dependent Smooth Muscle Conversion and Cardiomyocyte Hypertrophy—Full-length MYOCD has a limited capacity to transdifferentiate CH310T1/2 fibroblasts into smooth muscle cells (17Wang Z. Wang D.Z. Pipes G.C. Olson E.N. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 7129-7134Crossref PubMed Scopus (433) Google Scholar). Since truncations of MYOCD lacking the MHD show greater smooth muscle conversion than MYOCD935, we hypothesized that this phenomenon might be explained by MHD autoinhibition. We therefore tested whether introduction of MHD1-149 would repress MYOCD-dependent smooth muscle conversion (Fig. 4, A and B). MYOCDΔMHD converted ∼40! of transfected CH310T1/2 fibroblasts into SM-α-actin-positive cells within 7 days. Consistent with our in vitro reporter assay results, MHD1-149 inhibited the conversion efficiency of MYOCDΔMHD by about 50! (Fig. 4, A and B). Neither the RPEL motifs nor the MEF2-binding domain were necessary, but the two acidic residues (Asp-130, Glu-135) were required for effective inhibition of conversion (Fig. 4B). We next tested the mRNA transcript levels of multiple MYOCD target genes by quantitative RT-PCR to determine whether MHD-dependent inhibition affected genes other than SM-α-actin. MHD-dependent inhibition of MYOCD extended to multiple other direct MYOCD targets such as SM22α, ANF, and smooth muscle calponin (Fig. 4C). These targets were also dependent on Asp-130 and Glu-135. We also tested whether the MHD could affect MYOCD activity in cardiomyocytes. MYOCD induces a hypertrophic response in primary cardiomyocytes (18Xing W. Zhang T.C. Cao D. Wang Z. Antos C.L. Li S. Wang Y. Olson E.N. Wang D.Z. Circ. Res. 2006; 98: 1089-1097Crossref PubMed Scopus (139) Google Scholar, 23Badorff C. Seeger F.H. Zeiher A.M. Dimmeler S. Circ. Res. 2005; 97: 645-654Crossref PubMed Scopus (67) Google Scholar), and a dominant-negative form of MYOCD (DN-MYOCD) inhibits hypertrophy in response to chemicals such as PE. We investigated whether the MHD might mimic the DN-MYOCD effect. Indeed, WT but not DE → AA MHD 1-149 inhibited PE-induced cardiomyocyte hypertrophy, as assessed by measurements of cell surface area (Fig. 5, A and B). This observation suggests that the inhibition of hypertrophy was independent of MEF2 since the DE → AA mutant retains the MEF2-binding domain. The hypertrophic response is normally accompanied by an increase in expression of the ANF, brain natriuretic peptide (BNP (Nppb)), and skeletal muscle α-actin (Sk-α-actin (ACTA1)) transcripts and a decrease in GSK3β expression (18Xing W. Zhang T.C. Cao D. Wang Z. Antos C.L. Li S. Wang Y. Olson E.N. Wang D.Z. Circ. Res. 2006; 98: 1089-1097Crossref PubMed Scopus (139) Google Scholar, 23Badorff C. Seeger F.H. Zeiher A.M. Dimmeler S. Circ. Res. 2005; 97: 645-654Crossref PubMed Scopus (67) Google Scholar). Consistent with the calculations of surface area, DN-MYOCD and WT MHD inhibited the PE-induced changes in hypertrophic gene expression, and the DE → AA mutant MHD (Fig. 5C) displayed diminished inhibitory activity. This study shows that MYOCD has the potential for dynamic intramolecular regulation of the SRF-dependent gene program. A rare human mutation, K259R, resulted in attenuated activity of a cardiac isoform of myocardin without affecting a smooth muscle isoform that lacked the amino terminus. This observation led to the discovery that the amino terminus acted as an inhibitor of SRF-dependent myocardin activity. Although neither the MEF2-binding site nor the RPEL motifs in the amino terminus were necessary for this effect, we did find that two evolutionarily conserved acidic residues within the amino terminus were necessary for MHD-dependent inhibition. The K259R mutation was also more responsive to MHD-dependent inhibition, consistent with the notion that the K259R hypomorph is actually a gain of MHD-dependent inhibitory function. MRTF-B, the hypoactive MYOCD family member, showed increased transactivation potential when arginine 288 was mutated to lysine. This suggests that MHD-dependent inhibition may be a general mechanism for regulating the Myocardin family by utilizing the MYOCD Lys-259 and MRTF-B Arg-288 residue. The differential effects of the human K259R mutation on the function of MYOCD with or without MHD1-149 revealed novel aspects of MYOCD regulation. One interpretation of our finding is that the amino terminus of MYOCD sterically inhibits the SRF-binding domain and that the K259R mutation strengthens this intramolecular interaction between the MHD and the SRF-binding domain. In the smooth muscle form of MYOCD, the autoinhibitory domain (MHD) is absent; therefore, the K259R mutation is inconsequential. This function of the MHD, along with the interaction with MEF2, may explain the differential effect of MYOCD in cardiac and smooth muscle. Interestingly, inclusion of amino acids 149-195 in the MHD constructs increased the binding affinity and inhibitory activity of the MHD upon MYOCD. Of those 46 amino acids 25, or 54!, are conserved to amphibians, and nine of those are acidic (e.g. Asp-130 and Glu-135; data not shown). It is interesting to speculate that a direct interaction occurs between the negatively charged acidic residues of the MHD and the positively charged lysine at 259 or even the entire lysine-rich basic domain. Alternatively, the increased length of the arginine side chain, when compared with lysine, may disrupt MYOCD folding in a way that blocks SRF binding. In vitro, MYOCD protein is responsive to extracellular hypertrophic stimuli on synthetic promoters, apparently without altered steady state protein levels (18Xing W. Zhang T.C. Cao D. Wang Z. Antos C.L. Li S. Wang Y. Olson E.N. Wang D.Z. Circ. Res. 2006; 98: 1089-1097Crossref PubMed Scopus (139) Google Scholar). MYOCD is sumoylated by the PIAS1 ligase and associates with the histone acetyl-transferase p300, which also acetylates proteins (24Cao D. Wang Z. Zhang C.L. Oh J. Xing W. Li S. Richardson J.A. Wang D.Z. Olson E.N. Mol. Cell. Biol. 2005; 25: 364-376Crossref PubMed Scopus (147) Google Scholar, 25Wang J. Li A. Wang Z. Feng X. Olson E.N. Schwartz R.J. Mol. Cell. Biol. 2007; 27: 622-632Crossref PubMed Scopus (68) Google Scholar). Both of these activities are dependent upon lysine residues, and in these instances, arginine is not able to replace the post-translationally modified lysines (24Cao D. Wang Z. Zhang C.L. Oh J. Xing W. Li S. Richardson J.A. Wang D.Z. Olson E.N. Mol. Cell. Biol. 2005; 25: 364-376Crossref PubMed Scopus (147) Google Scholar, 25Wang J. Li A. Wang Z. Feng X. Olson E.N. Schwartz R.J. Mol. Cell. Biol. 2007; 27: 622-632Crossref PubMed Scopus (68) Google Scholar). Therefore, MYOCD may be post-translationally modified at Lys-259 to directly or allosterically disrupt MHD binding to MYOCD. Ultimately, the protein structure of MYOCD will help resolve the precise mechanism of MHD-mediated inhibition of the activity of MYOCD in cardiac tissue. The patient with the K259R mutation had a thickened pulmonic valve. Although we cannot be certain of the contribution of this mutation, the rarity of the mutation, evolutionary conservation, and the functional consequences would suggest that it is a contributing factor. Outflow tract valves are composed of early outflow tract myocardium, neural crest, and endocardial-derived cells (26Srivastava D. Cell. 2006; 126: 1037-1048Abstract Full Text Full Text PDF PubMed Scopus (511) Google Scholar). MYOCD-null mutant embryos only survive to embryonic day 10.5, before the formation of cardiac valves, precluding the ability to examine the role of MYOCD in these tissues (6Li S. Wang D.Z. Wang Z. Richardson J.A. Olson E.N. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 9366-9370Crossref PubMed Scopus (302) Google Scholar). Selective ablation of the MYOCD gene from neural crest resulted in patent ductus arteriousus but had no effect on valve morphogenesis (10Huang J. Cheng L. Li J. Chen M. Zhou D. Lu M.M. Proweller A. Epstein J.A. Parmacek M.S. J. Clin. Investig. 2008; 118: 515-525PubMed Google Scholar), although MYOCD may play a role in outflow myocardium or endocardium. To determine whether the K259R mutation contributed to the heart disease in the subject or co-segregated with the true disease-causing mutation as part of a haplotype block, further studies will be necessary, including generation of a mouse model of MYOCD K259R. If the knock-in mouse has outflow tract defects, it may provide a valuable tool for understanding valve development and disease. Most genes that are known to play a role in valve development (e.g. vascular endothelial growth factor, nuclear factor of activated T cells 1, and Notch1) are expressed in the endocardium of the prevalve tissue and respond to paracrine signals, such as transforming growth factor-β family members, which are released from the muscle tissue surrounding the valves (27Schroeder J.A. Jackson L.F. Lee D.C. Camenisch T.D. J. Mol. Med. 2003; 81: 392-403Crossref PubMed Scopus (159) Google Scholar). Since MYOCD is expressed in the myocardium, it may be well situated to induce such paracrine signals (1Wang D. Chang P.S. Wang Z. Sutherland L. Richardson J.A. Small E. Krieg P.A. Olson E.N. Cell. 2001; 105: 851-862Abstract Full Text Full Text PDF PubMed Scopus (756) Google Scholar). Myocardin expression is also induced by transforming growth factor-β, and it acts as a tumor suppressor in precancerous mesenchyme (28Milyavsky M. Shats I. Cholostoy A. Brosh R. Buganim Y. Weisz L. Kogan I. Cohen M. Shatz M. Madar S. Kalo E. Goldfinger N. Yuan J. Ron S. MacKenzie K. Eden A. Rotter V. Cancer Cell. 2007; 11: 133-146Abstract Full Text Full Text PDF PubMed Scopus (66) Google Scholar). Thus, MYOCD may be involved in guiding early cardiac mesenchymal progenitors into fully differentiated valve tissue, and any reduction in its activity could result in overproduction of undifferentiated valve progenitors and thickened valves. We thank E. N. Olson for advice, reagents, and generous help throughout the project and D. Z. Wang, G. Amarasinghe, and A. Muth for technical assistance. Download .pdf (.7 MB) Help with pdf files" @default.
• W2155264814 created "2016-06-24" @default.
• W2155264814 creator A5000381401 @default.
• W2155264814 creator A5001573379 @default.
• W2155264814 creator A5038288914 @default.
• W2155264814 creator A5064568347 @default.
• W2155264814 date "2008-12-01" @default.
• W2155264814 modified "2023-10-13" @default.
• W2155264814 title "A Rare Human Sequence Variant Reveals Myocardin Autoinhibition" @default.
• W2155264814 cites W1964820861 @default.
• W2155264814 cites W1967543638 @default.
• W2155264814 cites W1967738006 @default.
• W2155264814 cites W1998261642 @default.
• W2155264814 cites W2019222060 @default.
• W2155264814 cites W2025010136 @default.
• W2155264814 cites W2048660144 @default.
• W2155264814 cites W2055523288 @default.
• W2155264814 cites W2057307695 @default.
• W2155264814 cites W2060515857 @default.
• W2155264814 cites W2063490951 @default.
• W2155264814 cites W2070444361 @default.
• W2155264814 cites W2093723806 @default.
• W2155264814 cites W2096628719 @default.
• W2155264814 cites W2100195805 @default.
• W2155264814 cites W2101420772 @default.
• W2155264814 cites W2103680698 @default.
• W2155264814 cites W2111710873 @default.
• W2155264814 cites W2114403176 @default.
• W2155264814 cites W2121671306 @default.
• W2155264814 cites W2132216763 @default.
• W2155264814 cites W2134044324 @default.
• W2155264814 cites W2137346711 @default.
• W2155264814 cites W2145408676 @default.
• W2155264814 cites W2152376785 @default.
• W2155264814 cites W2169962597 @default.
• W2155264814 cites W3022305634 @default.
• W2155264814 doi "https://doi.org/10.1074/jbc.m805909200" @default.
• W2155264814 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2602885" @default.
• W2155264814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18852265" @default.
• W2155264814 hasPublicationYear "2008" @default.
• W2155264814 type Work @default.
• W2155264814 sameAs 2155264814 @default.
• W2155264814 citedByCount "16" @default.
• W2155264814 countsByYear W21552648142012 @default.
• W2155264814 countsByYear W21552648142013 @default.
• W2155264814 countsByYear W21552648142014 @default.
• W2155264814 countsByYear W21552648142015 @default.
• W2155264814 countsByYear W21552648142016 @default.
• W2155264814 countsByYear W21552648142019 @default.
• W2155264814 countsByYear W21552648142022 @default.
• W2155264814 countsByYear W21552648142023 @default.
• W2155264814 crossrefType "journal-article" @default.
• W2155264814 hasAuthorship W2155264814A5000381401 @default.
• W2155264814 hasAuthorship W2155264814A5001573379 @default.
• W2155264814 hasAuthorship W2155264814A5038288914 @default.
• W2155264814 hasAuthorship W2155264814A5064568347 @default.
• W2155264814 hasBestOaLocation W21552648141 @default.
• W2155264814 hasConcept C104317684 @default.
• W2155264814 hasConcept C185592680 @default.
• W2155264814 hasConcept C2778112365 @default.
• W2155264814 hasConcept C2780286377 @default.
• W2155264814 hasConcept C54355233 @default.
• W2155264814 hasConcept C69053785 @default.
• W2155264814 hasConcept C70721500 @default.
• W2155264814 hasConcept C86339819 @default.
• W2155264814 hasConcept C86803240 @default.
• W2155264814 hasConceptScore W2155264814C104317684 @default.
• W2155264814 hasConceptScore W2155264814C185592680 @default.
• W2155264814 hasConceptScore W2155264814C2778112365 @default.
• W2155264814 hasConceptScore W2155264814C2780286377 @default.
• W2155264814 hasConceptScore W2155264814C54355233 @default.
• W2155264814 hasConceptScore W2155264814C69053785 @default.
• W2155264814 hasConceptScore W2155264814C70721500 @default.
• W2155264814 hasConceptScore W2155264814C86339819 @default.
• W2155264814 hasConceptScore W2155264814C86803240 @default.
• W2155264814 hasIssue "51" @default.
• W2155264814 hasLocation W21552648141 @default.
• W2155264814 hasLocation W21552648142 @default.
• W2155264814 hasLocation W21552648143 @default.
• W2155264814 hasOpenAccess W2155264814 @default.
• W2155264814 hasPrimaryLocation W21552648141 @default.
• W2155264814 hasRelatedWork W2030227539 @default.
• W2155264814 hasRelatedWork W2057307695 @default.
• W2155264814 hasRelatedWork W2102569350 @default.
• W2155264814 hasRelatedWork W2110743056 @default.
• W2155264814 hasRelatedWork W2130456561 @default.
• W2155264814 hasRelatedWork W2150581509 @default.
• W2155264814 hasRelatedWork W2368302378 @default.
• W2155264814 hasRelatedWork W2552836056 @default.
• W2155264814 hasRelatedWork W2557281767 @default.
• W2155264814 hasRelatedWork W2602943915 @default.
• W2155264814 hasVolume "283" @default.
• W2155264814 isParatext "false" @default.
• W2155264814 isRetracted "false" @default.
• W2155264814 magId "2155264814" @default.
• W2155264814 workType "article" @default.